Inactivated influenza vaccine for intranasal immunization
Main Article Content
Abstract
Influenza is a major winter contagious respiratory disease that takes a high toll on the population due to wide range morbidity, complications, hospitalization and mortality. At present, vaccination is the most effective means for controlling influenza infection. Licensed vaccines include several forms of inactivated vaccines (trivalent, quadrivalent, whole virus, split and subunit) delivered by injection with or without adjuvants, and live attenuated vaccines for intranasal administration (LAIV). Type of vaccine and mode of administration dictate the induced immune response and efficiency of vaccination. It has been suggested that intranasal administration induces better protection, as it neutralizes the virus at its entry site, eliciting production of secretory IgA (SIgA) antibodies and a serum barrier. In contrast, following injection, SIgA antibodies are produced only in negligible amounts. Another type of vaccine under clinical investigation is inactivated virus for intranasal application. This type of vaccine induces local (SIgA) and serum responses similar to the LAIV vaccines. Moreover, inactivated vaccines may be suitable for high-risk groups, which are constantly expanding, for whom live vaccines (approved only for healthy 2-49 years old) are inappropriate. The main obstacles toward successful vaccination are the annual changes in the virus (drift and occasional shift), appearance of new pandemic strains not included in the vaccine and transmission of pathogenic avian strains to humans. Efforts to develop a universal vaccine, which will protect against all A strains, might be a solution. Intranasal application of a universal vaccine to mice protected vaccinated animals from lethal infection by heterologous strains and furthermore reduced the transmission of virus from vaccinated to non-vaccinated mice. It may be concluded that intranasal inactivated virus formulas, either whole (without adjuvant), split (with adjuvant) or universal, may be the future vaccine for influenza.
Article Details
How to Cite
ZAKAY-RONES, Zichria.
Inactivated influenza vaccine for intranasal immunization.
Medical Research Archives, [S.l.], v. 5, n. 8, aug. 2017.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/1428>. Date accessed: 15 nov. 2024.
Keywords
influenza vaccines, inactivated vaccine, universal vaccines, intranasal administration
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Kyeyagalire R, Tempia S, Cohen AL, Smith AD, McAnerney JM, Dermaux-Msimang V, et al. Hospitalizations associated with influenza and respiratory syncytial virus among patients attending a network of private hospitals in South Africa, 2007-2012. BMC infectious diseases. 2014;14:694.
2. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917-30.
3. Lafond KE, Nair H, Rasooly MH, Valente F, Booy R, Rahman M, et al. Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982-2012: A Systematic Analysis. PLoS medicine. 2016;13(3):e1001977.
4. Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status. Influenza and other respiratory viruses. 2014;8(5):507-15.
5. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet. 2003;362(9397):1733-45.
6. Lemaitre M, Carrat F, Rey G, Miller M, Simonsen L, Viboud C. Mortality burden of the 2009 A/H1N1 influenza pandemic in France: comparison to seasonal influenza and the A/H3N2 pandemic. PloS one. 2012;7(9):e45051.
7. Hibbert CL, Piedra PA, McLaurin KK, Vesikari T, Mauskopf J, Mahadevia PJ. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine. 2007;25(47):8010-20.
8. Writing Committee of the WHOCoCAoPI, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. The New England journal of medicine. 2010;362(18):1708-19.
9. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morbidity and mortality weekly report.59:1057-6.
10. Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States. Vaccine. 2008;26(23):2841-8.
11. Zakay-Rones Z. Human influenza vaccines and assessment of immunogenicity. Expert review of vaccines. 2010;9(12):1423-39.
12. Oliveira Jde F, Boing AF, Waldman EA, Antunes JL. Ecological study on mortality from influenza and pneumonia before and after influenza vaccination in the Northeast and South of Brazil. Cadernos de saude publica. 2013;29(12):2535-45.
13. Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, et al. Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports. 2016;65(5):1-54.
14. Stohr K, Bucher D, Colgate T, Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture. Methods in molecular biology. 2012;865:147-62.
15. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31(5):770-6.
16. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Human vaccines & immunotherapeutics. 2012;8(1):81-8.
17. Antunes JL, Waldman EA, Borrell C, Paiva TM. Effectiveness of influenza vaccination and its impact on health inequalities. International journal of epidemiology. 2007;36(6):1319-26.
18. Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. Journal of medical virology. 2003;69(4):560-7.
19. Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine. 2008;26 Suppl 4:D5-9.
20. Montomoli E, Khadang B, Piccirella S, Trombetta C, Mennitto E, Manini I, et al. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production. Expert review of vaccines. 2012;11(5):587-94.
21. Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2011;377(9767):751-9.
22. Barrett PN, Portsmouth D, Ehrlich HJ. Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development. Expert review of vaccines. 2013;12(4):395-413.
23. Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. The New England journal of medicine. 2008;358(24):2573-84.
24. Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, et al. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012;54(7):946-54.
25. Shin D, Park KJ, Lee H, Cho EY, Kim MS, Hwang MH, et al. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines. Virus research. 2015;204:40-6.
26. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;62(9):1092-9.
27. Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP. Fluzone(R) High-Dose Influenza Vaccine. Expert review of vaccines. 2016;15(12):1495-505.
28. Cate TR, Rayford Y, Nino D, Winokur P, Brady R, Belshe R, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine. 2010;28(9):2076-9.
29. Keren G, Segev S, Morag A, Zakay-Rones Z, Barzilai A, Rubinstein E. Failure of influenza vaccination in the aged. Journal of medical virology. 1988;25(1):85-9.
30. Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine. 2006;24(7):1035-43.
31. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, et al. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morbidity and mortality weekly report. 2015;64(1):10-5.
32. Flannery B, Reynolds SB, Blanton L, Santibanez TA, O'Halloran A, Lu PJ, et al. Influenza Vaccine Effectiveness Against Pediatric Deaths: 2010-2014. Pediatrics. 2017;139(5).
33. Recommendations of the ACIP: prevention and control of seasonal influenza with vaccines
In: CDC M, editor. 2009. p. 1-52
34. Gasparini R, Amicizia D, Lai PL, Panatto D. Live attenuated influenza vaccine--a review. Journal of preventive medicine and hygiene. 2011;52(3):95-101.
35. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. The New England journal of medicine. 2007;356(7):685-96.
36. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. Journal of virology. 2006;80(23):11756-66.
37. Wang L, Liu SY, Chen HW, Xu J, Chapon M, Zhang T, et al. Generation of a Live Attenuated Influenza Vaccine that Elicits Broad Protection in Mice and Ferrets. Cell host & microbe. 2017;21(3):334-43.
38. Waldman RH, Mann JJ, Small PA, Jr. Immunization against influenza. Prevention of illness in man by aerosolized inactivated vaccine. Jama. 1969;207(3):520-4.
39. Kuno-Sakai H. [Intranasal application of inactivated influenza virus vaccines]. Nihon rinsho Japanese journal of clinical medicine. 1997;55(10):2738-45.
40. Potter CW, Jennings R. Intranasal immunization with inactivated influenza vaccine. Pharmaceutical science & technology today. 1999;2(10):402-8.
41. Muszkat M, Friedman G, Schein MH, Naveh P, Greenbaum E, Schlesinger M, et al. Local SIgA response following administration of a novel intranasal inactivated influenza virus vaccine in community residing elderly. Vaccine. 2000;18(16):1696-9.
42. Muszkat M, Yehuda AB, Schein MH, Friedlander Y, Naveh P, Greenbaum E, et al. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. Journal of medical virology. 2000;61(1):100-6.
43. Muszkat M, Greenbaum E, Ben-Yehuda A, Oster M, Yeu'l E, Heimann S, et al. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine. 2003;21(11-12):1180-6.
44. Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, et al. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine. Journal of medical virology. 2001;65(1):178-84.
45. Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, et al. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine. 2002;20(7-8):1232-9.
46. Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine. 2004;22(20):2566-77.
47. Kiderman A, Furst A, Stewart B, Greenbaum E, Morag A, Zakay-Rones Z. A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997-98. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2001;20(3):155-61.
48. Muhamed G, Greenbaum E, Zakay-Rones Z. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. The Israel Medical Association journal : IMAJ. 2006;8(3):155-8.
49. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine. 2003;21(23):3212-8.
50. Gluck R, Mischler R, Durrer P, Furer E, Lang AB, Herzog C, et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. The Journal of infectious diseases. 2000;181(3):1129-32.
51. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. The New England journal of medicine. 2004;350(9):896-903.
52. Fiore AE, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep: 2009.
53. Ambrose CS, Bright H, Mallory R. Letter to the editor: Potential causes of the decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2016;21(45).
54. Quan FS, Compans RW, Nguyen HH, Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. Journal of virology. 2008;82(3):1350-9.
55. Hashigucci K, Ogawa H, Ishidate T, Yamashita R, Kamiya H, Watanabe K, et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine. 1996;14(2):113-9.
56. Tamura S. Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine. 2010;28(38):6393-7.
57. Tamura SI, Samegai Y, Kurata H, Kikuta K, Nagamine T, Aizawa C, et al. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine. 1989;7(3):257-62.
58. Hasegawa H, Ichinohe T, Ainai A, Tamura S, Kurata T. Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses. Therapeutics and clinical risk management. 2009;5(1):125-32.
59. Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. The Journal of infectious diseases. 2007;196(9):1313-20.
60. Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, Kawaguchi A, et al. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. Journal of medical virology. 2010;82(10):1754-61.
61. Maltais AK, Stittelaar KJ, Veldhuis Kroeze EJ, van Amerongen G, Dijkshoorn ML, Krestin GP, et al. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets. Vaccine. 2014;32(26):3307-15.
62. Chua BY, Wong CY, Mifsud EJ, Edenborough KM, Sekiya T, Tan AC, et al. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity. mBio. 2015;6(6):e01024-15.
63. Saito S, Ainai A, Suzuki T, Harada N, Ami Y, Yuki Y, et al. The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine. Vaccine. 2016;34(9):1201-7.
64. Furuya Y. Return of inactivated whole-virus vaccine for superior efficacy. Immunology and cell biology. 2012;90(6):571-8.
65. Haredy AM, Takenaka N, Yamada H, Sakoda Y, Okamatsu M, Yamamoto N, et al. An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice. Clinical and vaccine immunology : CVI. 2013;20(7):998-1007.
66. Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. Journal of virology. 2006;80(10):4962-70.
67. Ainai A, Tamura S, Suzuki T, van Riet E, Ito R, Odagiri T, et al. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Human vaccines & immunotherapeutics. 2013;9(9):1962-70.
68. Ainai A, Tamura S, Suzuki T, Ito R, Asanuma H, Tanimoto T, et al. Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine. Journal of medical virology. 2012;84(2):336-44.
69. Tamura S, Ainai A, Suzuki T, Kurata T, Hasegawa H. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine? Japanese journal of infectious diseases. 2016;69(3):165-79.
70. Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, et al. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clinical and vaccine immunology : CVI. 2012;19(7):979-90.
71. Overton ET, Goepfert PA, Cunningham P, Carter WA, Horvath J, Young D, et al. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans. Vaccine. 2014;32(42):5490-5.
72. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. The New England journal of medicine. 2014;370(6):520-32.
73. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. The New England journal of medicine. 2013;368(20):1888-97.
74. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, et al. A distinct lineage of influenza A virus from bats. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(11):4269-74.
75. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine. 2015;33(1):246-51.
76. Liu X, Liu Y, Zhang Y, Chen Z, Tang Z, Xu Q, et al. Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population. PloS one. 2013;8(3):e58810.
77. Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science. 2016;354(6313):722-6.
78. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011;333(6044):843-50.
79. Egorov AY. The challenges of creating a universal influenza vaccine. MIR Journal. 2016;3(1).
80. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nature medicine. 2010;16(12):1389-91.
81. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio. 2010;1(1).
82. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850-6.
83. Bianchi E, Liang X, Ingallinella P, Finotto M, Chastain MA, Fan J, et al. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. Journal of virology. 2005;79(12):7380-8.
84. Krammer F. Novel universal influenza virus vaccine approaches. Current opinion in virology. 2016;17:95-103.
85. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, et al. Highly conserved protective epitopes on influenza B viruses. Science. 2012;337(6100):1343-8.
86. Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, et al. What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine. 2016;8:277-90.
87. Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nature medicine. 2015;21(9):1065-70.
88. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. Journal of immunology. 2011;186(2):1022-31.
89. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert review of vaccines. 2009;8(4):499-508.
90. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology. 2005;337(1):149-61.
91. Hatta M, Kawaoka Y. The NB protein of influenza B virus is not necessary for virus replication in vitro. Journal of virology. 2003;77(10):6050-4.
92. Wraith DC, Vessey AE, Askonas BA. Purified influenza virus nucleoprotein protects mice from lethal infection. The Journal of general virology. 1987;68 ( Pt 2):433-40.
93. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine. 2005;23(46-47):5404-10.
94. Gschoesser C, Almanzar G, Hainz U, Ortin J, Schonitzer D, Schild H, et al. CD4+ and CD8+ mediated cellular immune response to recombinant influenza nucleoprotein. Vaccine. 2002;20(31-32):3731-8.
95. Zhirnov OP, Isaeva EI, Konakova TE, Thoidis G, Piskareva LM, Akopova, II, et al. Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Influenza and other respiratory viruses. 2007;1(2):71-9.
96. Gilbert SC. Advances in the development of universal influenza vaccines. Influenza and other respiratory viruses. 2013;7(5):750-8.
97. Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, Nakajima K, et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. Journal of immunology. 1996;156(10):3892-900.
98. Epstein SL, Price GE. Cross-protective immunity to influenza A viruses. Expert review of vaccines. 2010;9(11):1325-41.
99. Price GE, Lo CY, Misplon JA, Epstein SL. Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model. Journal of virology. 2014;88(11):6019-30.
100. Schwartzman LM, Cathcart AL, Pujanauski LM, Qi L, Kash JC, Taubenberger JK. An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus. mBio. 2015;6(4):e01044.
101. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? Journal of immunology. 2009;183(11):6883-92.
102. Corthesy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Frontiers in immunology. 2013;4:185.
103. Suzuki T, Kawaguchi A, Ainai A, Tamura S, Ito R, Multihartina P, et al. Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(25):7809-14.
104. Tanimoto T, Haredy AM, Takenaka N, Tamura S, Okuno Y, Mori Y, et al. Comparison of the cross-reactive anti-influenza neutralizing activity of polymeric and monomeric IgA monoclonal antibodies. Viral immunology. 2012;25(5):433-9.
105. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flano E, Schindler C, et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. Journal of virology. 2010;84(21):11515-22.
106. Krammer F, Pica N, Hai R, Tan GS, Palese P. Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice. Journal of virology. 2012;86(19):10302-7.
2. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917-30.
3. Lafond KE, Nair H, Rasooly MH, Valente F, Booy R, Rahman M, et al. Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982-2012: A Systematic Analysis. PLoS medicine. 2016;13(3):e1001977.
4. Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status. Influenza and other respiratory viruses. 2014;8(5):507-15.
5. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet. 2003;362(9397):1733-45.
6. Lemaitre M, Carrat F, Rey G, Miller M, Simonsen L, Viboud C. Mortality burden of the 2009 A/H1N1 influenza pandemic in France: comparison to seasonal influenza and the A/H3N2 pandemic. PloS one. 2012;7(9):e45051.
7. Hibbert CL, Piedra PA, McLaurin KK, Vesikari T, Mauskopf J, Mahadevia PJ. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine. 2007;25(47):8010-20.
8. Writing Committee of the WHOCoCAoPI, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. The New England journal of medicine. 2010;362(18):1708-19.
9. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morbidity and mortality weekly report.59:1057-6.
10. Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States. Vaccine. 2008;26(23):2841-8.
11. Zakay-Rones Z. Human influenza vaccines and assessment of immunogenicity. Expert review of vaccines. 2010;9(12):1423-39.
12. Oliveira Jde F, Boing AF, Waldman EA, Antunes JL. Ecological study on mortality from influenza and pneumonia before and after influenza vaccination in the Northeast and South of Brazil. Cadernos de saude publica. 2013;29(12):2535-45.
13. Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, et al. Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports. 2016;65(5):1-54.
14. Stohr K, Bucher D, Colgate T, Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture. Methods in molecular biology. 2012;865:147-62.
15. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31(5):770-6.
16. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Human vaccines & immunotherapeutics. 2012;8(1):81-8.
17. Antunes JL, Waldman EA, Borrell C, Paiva TM. Effectiveness of influenza vaccination and its impact on health inequalities. International journal of epidemiology. 2007;36(6):1319-26.
18. Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. Journal of medical virology. 2003;69(4):560-7.
19. Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine. 2008;26 Suppl 4:D5-9.
20. Montomoli E, Khadang B, Piccirella S, Trombetta C, Mennitto E, Manini I, et al. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production. Expert review of vaccines. 2012;11(5):587-94.
21. Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2011;377(9767):751-9.
22. Barrett PN, Portsmouth D, Ehrlich HJ. Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development. Expert review of vaccines. 2013;12(4):395-413.
23. Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. The New England journal of medicine. 2008;358(24):2573-84.
24. Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, et al. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012;54(7):946-54.
25. Shin D, Park KJ, Lee H, Cho EY, Kim MS, Hwang MH, et al. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines. Virus research. 2015;204:40-6.
26. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;62(9):1092-9.
27. Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP. Fluzone(R) High-Dose Influenza Vaccine. Expert review of vaccines. 2016;15(12):1495-505.
28. Cate TR, Rayford Y, Nino D, Winokur P, Brady R, Belshe R, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine. 2010;28(9):2076-9.
29. Keren G, Segev S, Morag A, Zakay-Rones Z, Barzilai A, Rubinstein E. Failure of influenza vaccination in the aged. Journal of medical virology. 1988;25(1):85-9.
30. Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine. 2006;24(7):1035-43.
31. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, et al. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morbidity and mortality weekly report. 2015;64(1):10-5.
32. Flannery B, Reynolds SB, Blanton L, Santibanez TA, O'Halloran A, Lu PJ, et al. Influenza Vaccine Effectiveness Against Pediatric Deaths: 2010-2014. Pediatrics. 2017;139(5).
33. Recommendations of the ACIP: prevention and control of seasonal influenza with vaccines
In: CDC M, editor. 2009. p. 1-52
34. Gasparini R, Amicizia D, Lai PL, Panatto D. Live attenuated influenza vaccine--a review. Journal of preventive medicine and hygiene. 2011;52(3):95-101.
35. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. The New England journal of medicine. 2007;356(7):685-96.
36. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. Journal of virology. 2006;80(23):11756-66.
37. Wang L, Liu SY, Chen HW, Xu J, Chapon M, Zhang T, et al. Generation of a Live Attenuated Influenza Vaccine that Elicits Broad Protection in Mice and Ferrets. Cell host & microbe. 2017;21(3):334-43.
38. Waldman RH, Mann JJ, Small PA, Jr. Immunization against influenza. Prevention of illness in man by aerosolized inactivated vaccine. Jama. 1969;207(3):520-4.
39. Kuno-Sakai H. [Intranasal application of inactivated influenza virus vaccines]. Nihon rinsho Japanese journal of clinical medicine. 1997;55(10):2738-45.
40. Potter CW, Jennings R. Intranasal immunization with inactivated influenza vaccine. Pharmaceutical science & technology today. 1999;2(10):402-8.
41. Muszkat M, Friedman G, Schein MH, Naveh P, Greenbaum E, Schlesinger M, et al. Local SIgA response following administration of a novel intranasal inactivated influenza virus vaccine in community residing elderly. Vaccine. 2000;18(16):1696-9.
42. Muszkat M, Yehuda AB, Schein MH, Friedlander Y, Naveh P, Greenbaum E, et al. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. Journal of medical virology. 2000;61(1):100-6.
43. Muszkat M, Greenbaum E, Ben-Yehuda A, Oster M, Yeu'l E, Heimann S, et al. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine. 2003;21(11-12):1180-6.
44. Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, et al. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine. Journal of medical virology. 2001;65(1):178-84.
45. Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M, et al. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine. 2002;20(7-8):1232-9.
46. Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine. 2004;22(20):2566-77.
47. Kiderman A, Furst A, Stewart B, Greenbaum E, Morag A, Zakay-Rones Z. A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997-98. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2001;20(3):155-61.
48. Muhamed G, Greenbaum E, Zakay-Rones Z. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. The Israel Medical Association journal : IMAJ. 2006;8(3):155-8.
49. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine. 2003;21(23):3212-8.
50. Gluck R, Mischler R, Durrer P, Furer E, Lang AB, Herzog C, et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. The Journal of infectious diseases. 2000;181(3):1129-32.
51. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. The New England journal of medicine. 2004;350(9):896-903.
52. Fiore AE, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep: 2009.
53. Ambrose CS, Bright H, Mallory R. Letter to the editor: Potential causes of the decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2016;21(45).
54. Quan FS, Compans RW, Nguyen HH, Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. Journal of virology. 2008;82(3):1350-9.
55. Hashigucci K, Ogawa H, Ishidate T, Yamashita R, Kamiya H, Watanabe K, et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine. 1996;14(2):113-9.
56. Tamura S. Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine. 2010;28(38):6393-7.
57. Tamura SI, Samegai Y, Kurata H, Kikuta K, Nagamine T, Aizawa C, et al. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine. 1989;7(3):257-62.
58. Hasegawa H, Ichinohe T, Ainai A, Tamura S, Kurata T. Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses. Therapeutics and clinical risk management. 2009;5(1):125-32.
59. Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. The Journal of infectious diseases. 2007;196(9):1313-20.
60. Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, Kawaguchi A, et al. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. Journal of medical virology. 2010;82(10):1754-61.
61. Maltais AK, Stittelaar KJ, Veldhuis Kroeze EJ, van Amerongen G, Dijkshoorn ML, Krestin GP, et al. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets. Vaccine. 2014;32(26):3307-15.
62. Chua BY, Wong CY, Mifsud EJ, Edenborough KM, Sekiya T, Tan AC, et al. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity. mBio. 2015;6(6):e01024-15.
63. Saito S, Ainai A, Suzuki T, Harada N, Ami Y, Yuki Y, et al. The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine. Vaccine. 2016;34(9):1201-7.
64. Furuya Y. Return of inactivated whole-virus vaccine for superior efficacy. Immunology and cell biology. 2012;90(6):571-8.
65. Haredy AM, Takenaka N, Yamada H, Sakoda Y, Okamatsu M, Yamamoto N, et al. An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice. Clinical and vaccine immunology : CVI. 2013;20(7):998-1007.
66. Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. Journal of virology. 2006;80(10):4962-70.
67. Ainai A, Tamura S, Suzuki T, van Riet E, Ito R, Odagiri T, et al. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Human vaccines & immunotherapeutics. 2013;9(9):1962-70.
68. Ainai A, Tamura S, Suzuki T, Ito R, Asanuma H, Tanimoto T, et al. Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine. Journal of medical virology. 2012;84(2):336-44.
69. Tamura S, Ainai A, Suzuki T, Kurata T, Hasegawa H. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine? Japanese journal of infectious diseases. 2016;69(3):165-79.
70. Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, et al. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clinical and vaccine immunology : CVI. 2012;19(7):979-90.
71. Overton ET, Goepfert PA, Cunningham P, Carter WA, Horvath J, Young D, et al. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans. Vaccine. 2014;32(42):5490-5.
72. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. The New England journal of medicine. 2014;370(6):520-32.
73. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. The New England journal of medicine. 2013;368(20):1888-97.
74. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, et al. A distinct lineage of influenza A virus from bats. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(11):4269-74.
75. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine. 2015;33(1):246-51.
76. Liu X, Liu Y, Zhang Y, Chen Z, Tang Z, Xu Q, et al. Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population. PloS one. 2013;8(3):e58810.
77. Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science. 2016;354(6313):722-6.
78. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011;333(6044):843-50.
79. Egorov AY. The challenges of creating a universal influenza vaccine. MIR Journal. 2016;3(1).
80. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nature medicine. 2010;16(12):1389-91.
81. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio. 2010;1(1).
82. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850-6.
83. Bianchi E, Liang X, Ingallinella P, Finotto M, Chastain MA, Fan J, et al. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. Journal of virology. 2005;79(12):7380-8.
84. Krammer F. Novel universal influenza virus vaccine approaches. Current opinion in virology. 2016;17:95-103.
85. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, et al. Highly conserved protective epitopes on influenza B viruses. Science. 2012;337(6100):1343-8.
86. Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, et al. What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine. 2016;8:277-90.
87. Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nature medicine. 2015;21(9):1065-70.
88. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. Journal of immunology. 2011;186(2):1022-31.
89. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert review of vaccines. 2009;8(4):499-508.
90. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology. 2005;337(1):149-61.
91. Hatta M, Kawaoka Y. The NB protein of influenza B virus is not necessary for virus replication in vitro. Journal of virology. 2003;77(10):6050-4.
92. Wraith DC, Vessey AE, Askonas BA. Purified influenza virus nucleoprotein protects mice from lethal infection. The Journal of general virology. 1987;68 ( Pt 2):433-40.
93. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine. 2005;23(46-47):5404-10.
94. Gschoesser C, Almanzar G, Hainz U, Ortin J, Schonitzer D, Schild H, et al. CD4+ and CD8+ mediated cellular immune response to recombinant influenza nucleoprotein. Vaccine. 2002;20(31-32):3731-8.
95. Zhirnov OP, Isaeva EI, Konakova TE, Thoidis G, Piskareva LM, Akopova, II, et al. Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Influenza and other respiratory viruses. 2007;1(2):71-9.
96. Gilbert SC. Advances in the development of universal influenza vaccines. Influenza and other respiratory viruses. 2013;7(5):750-8.
97. Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, Nakajima K, et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. Journal of immunology. 1996;156(10):3892-900.
98. Epstein SL, Price GE. Cross-protective immunity to influenza A viruses. Expert review of vaccines. 2010;9(11):1325-41.
99. Price GE, Lo CY, Misplon JA, Epstein SL. Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model. Journal of virology. 2014;88(11):6019-30.
100. Schwartzman LM, Cathcart AL, Pujanauski LM, Qi L, Kash JC, Taubenberger JK. An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus. mBio. 2015;6(4):e01044.
101. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? Journal of immunology. 2009;183(11):6883-92.
102. Corthesy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Frontiers in immunology. 2013;4:185.
103. Suzuki T, Kawaguchi A, Ainai A, Tamura S, Ito R, Multihartina P, et al. Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(25):7809-14.
104. Tanimoto T, Haredy AM, Takenaka N, Tamura S, Okuno Y, Mori Y, et al. Comparison of the cross-reactive anti-influenza neutralizing activity of polymeric and monomeric IgA monoclonal antibodies. Viral immunology. 2012;25(5):433-9.
105. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flano E, Schindler C, et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. Journal of virology. 2010;84(21):11515-22.
106. Krammer F, Pica N, Hai R, Tan GS, Palese P. Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice. Journal of virology. 2012;86(19):10302-7.